세계의 표적 단백질 분해 치료제 시장

Rapid Technology Advances Bolster a Robust Therapeutic Pipeline

This Frost & Sullivan research report provides an in-depth analysis of the emerging targeted protein degradation (TPD) space. TPD strategies enable treating various diseases not yet treatable via conventional approaches by attacking disease-causing proteins in a controlled manner, thus reducing the risk of side effects.

It is estimated that 80% of a cell's proteome cannot be targeted via traditional approaches such as small molecule inhibitors, ASO, or monoclonal antibodies, which has led to the development of TPD approaches. Indeed, TPD has advanced enormously in the last two decades, and PROTACs have emerged as the most common protein degrader researched until now. As new technologies emerge, several types of protein degraders have been developed.

Two main types exist: intracellular and extracellular degraders. Until now, intracellular protein degraders have been the most extensively studied. These degrade intracellular proteins by leveraging the ubiquitin-proteasomal degradation pathway, but an estimated 40% of genes encoding extracellular and membrane-associated proteins cannot be targeted by intracellular protein degraders, leading to the development of extracellular protein degradation.

Increased private and public funding is an important factor driving the growth of targeted protein degradation technology. This report includes an analysis of funding trends in the TPD space.

This report discusses the different types of extracellular and intracellular protein degraders and R&D focus areas; it analyses the applicability of different degraders across various diseases and identifies their clinical translation and related key players. Finally, Frost & Sullivan has identified four growth opportunities for TPD that could potentially transform the market.

Questions that this report seeks to answer include:

• 1. What are the key drivers or challenges for TPD development?

• 2. How do the private funding and partnership landscapes look for TPD?

• 3. Who are the key industry participants developing targeted protein degraders?

• 4. What are the R&D trends emerging across TPD that could further shape the development of protein degraders?

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Targeted Protein Degradation Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology
• Introduction

Growth Opportunity Analysis

• Growth Drivers
• Growth Driver Analysis
• Growth Restraints
• Growth Restraints Analysis
• Scope of Analysis
• Segmentation
• The Need for Targeted Protein Degraders

R&D and Innovation Ecosystem

• TPD-Evolution and Clinical aspect
• Intracellular Targeted Protein Degraders in Clinical Development
• Intracellular Targeted Protein Degraders-PROTACs
• Emerging Intracellular Targeted Protein Degraders
• Innovation Spotlight-Intracellular Protein Degradation
• Development of Extracellular Protein Degradation Therapeutics
• Challenges for Extracellular Protein Degrader Development
• Extracellular Protein Degradation Approaches
• Emerging Classes of Extracellular Protein Degraders
• Innovation Spotlight-Extracellular Protein Degradation
• Key Differences Between Extracellular and Intracellular Protein Targeting
• Targeted Protein Degradation Technology Snapshot

R&D Focus and Application Landscape

• R&D Innovation Trends
• Protein Degraders in Healthcare and Beyond
• Protein Degraders across Different Disease Areas
• Key Players and Therapeutics Areas of Focus
• Protein Degraders Innovation Landscape

Market Dynamics

• Public and Private Funding for TPD Therapy Development
• Partnership Landscape of Biopharma Companies in TPD Therapeutics Development
• TPD Companies' Partnerships for Developing TPD Therapeutics

Growth Opportunity Universe

• Growth Opportunity 1: Efficient and Tissue-specific Degrader Delivery
• Growth Opportunity 2: Novel E3 Ligases Discovery and Design
• Growth Opportunity 3: Advanced PROTACs Development
• Growth Opportunity 4: Research and Product Development Partnerships to Develop Next-gen TPD Therapeutics

Appendix

• Appendix
• Appendix

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• Legal Disclaimer